Author |
Title |
JournalName |
Year D |
Click on Column Headers to Re-Sort The Current List |
Burroughs W |
Letter From A Master Addict To Dangerous Drugs |
British Journal of A... |
1956 |
Dhawan BN |
Effect of drugs on LSD-25 induced pyrexia in rabbits. |
Arch.internat.de pha... |
1959 |
Heninger GR, Bowers MB |
Adverse effects of niacin in emergent psychosis |
Journal American Med... |
1968 |
Nichols DE |
Potential Psychotomimetics Bromomethoxyamphetamines And Structural Con... |
Diss.Abstr.Intern. B |
1973 |
Andén NE, Corrodi H, Fuxe... |
Hallucinogenic Phenylethylamines: Interactions with Serotonin Turnover... |
Eur J Pharmacol |
1974 |
Ananth J |
Congenital malformations with psychopharmacologic agents |
Comprehensive Psychi... |
1975 |
MacDonald JF |
Pharmacology of dopamine receptors in the central nervous system of Pl... |
J.Physiol. |
1976 |
Edvinsson L, Hardebo JE, ... |
Pharmacological Analysis of 5-Hydroxytryptamine Receptors in Isolated ... |
Circulation Res. |
1978 |
Samanin R, Mennini T, Fer... |
m-Chlorophenylpiperazine: A Central Serotonin Agonist Causing Powerful... |
Naunyn-Schmiedeberg'... |
1979 |
Editorial |
Arguments Heard for Psychedelics Probe |
Science |
1980 |
McNall SJ, Mansour TE |
A Novel Serotonin Receptor In The Liver Fluke Fasciola Hepatica. |
Federation Proceedin... |
1983 |
Vandermaelen CP, Aghajani... |
Electrophysiological and Pharmacological Characterization of Serotoner... |
Brain Research |
1983 |
Mamounas LA, Molliver ME |
Evidence for dual serotonergic projections to neocortex: axons from th... |
Exp Neurol |
1988 |
Jamieson DD, Duffield PH,... |
Comparison of the central nervous system activity of the aqueous and l... |
Arch Int Pharmacodyn... |
1989 |
Nash JF, Nichols DE |
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurall... |
Eur J Pharmacol |
1991 |
Nichols DE, Johnson MP, O... |
5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine |
Pharmacol Biochem Be... |
1991 |
Lehmann J, DeSouza EB, Cu... |
Regional distribution to recovery of 5-HT levels after administration ... |
Ann N Y Acad Sci |
1992 |
Hashimoto K |
Effects of benzylpiperazine derivatives on the acute effects of 3,4-me... |
Neurosci Lett |
1993 |
Monte AP, Marona-Lewicka ... |
Synthesis and pharmacological examination of benzofuran, indan, and te... |
J Med Chem |
1993 |
Chu T, Kumagai Y, DiStefa... |
Disposition of methylenedioxymethamphetamine and three metabolites in ... |
Biochem Pharmacol |
1996 |
Finch E, Sell L, Arnold D |
Drug workers emphasise that water is not an antidote to drug |
BMJ |
1996 |
Boys A, Lenton S, Norcros... |
Polydrug use at raves by a Western Australian sample |
Drug & Alcohol Revie... |
1997 |
De Souza I, Kelly JP, Har... |
An appraisal of the pharmacological and toxicological effects of a sin... |
Pharmacol Toxicol |
1997 |
Plessinger MA |
Prenatal exposure to amphetamines. Risks and adverse outcomes in pregn... |
Obstet Gynecol Clin ... |
1998 |
Akram G, Galt M |
A profile of harm-reduction practices and co-use of illicit and licit ... |
Drugs: Education, Pr... |
1999 |
Sexton TJ, McEvoy C, Neum... |
(+) 3,4-methylenedioxymethamphetamine ('ecstasy') transiently increase... |
Mol Psychiatry |
1999 |
Vollenweider FX, Gamma A,... |
Is a single dose of MDMA harmless? |
Neuropsychopharmacol... |
1999 |
Navarro JF, Maldonado E |
Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in ago... |
Prog Neuropsychophar... |
1999 |
Vollenweider FX, Remensbe... |
Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensor... |
Psychopharmacology (... |
1999 |
Weir E |
Raves: a review of the culture, the drugs and the prevention of harm |
Canadian Medical Ass... |
2000 |
Weinbroum AA, Rudick V, P... |
The role of dextromethorphan in pain control |
Can J Anaesth |
2000 |
Winstock AR, Griffiths P,... |
Drugs and the dance music scene: a survey of current drug use patterns... |
Drug and Alcohol Dep... |
2000 |
Shewan D, Dalgarno P, Rei... |
Perceived risk and risk reduction among ecstasy users; the role of dru... |
International Journa... |
2000 |
Jasinski DR |
An evaluation of the abuse potential of madafinil using methylphenidat... |
J Psychopharmacology |
2000 |
Varon J, Marik PE |
The diagnosis and management of hypertensive crises |
Chest |
2000 |
Vastag B |
Ecstasy experts want realistic messages |
JAMA |
2001 |
Chambers JJ, Kurrasch-Orb... |
Enantiospecific synthesis and pharmacological evaluation of a series o... |
J Med Chem |
2001 |
Hansen D, Maycock B, Lowe... |
'Weddings, parties, anything…', a qualitative analysis of ecstasy use ... |
International Journa... |
2001 |
Winstock AR, Wolff K, Ram... |
Ecstasy pill testing: harm minimization gone too far? |
Addiction |
2001 |
Baggott M |
Preventing problems in ecstasy users; Reduce use to reduce harm |
J Psychoactive Drugs |
2002 |
Hayner, GN |
MDMA misrepresentation: An unresolved problem for ecstasy users |
J Psychoactive Drugs |
2002 |
Bellis MA, Hughes K, Lowe... |
Healthy nightclubs and recreational substance use. From a harm minimis... |
Addict Behav |
2002 |
Navarro JF, Maldonado E |
Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mi... |
Prog Neuropsychophar... |
2002 |
Engelsman EL |
Cannabis Control: the model of the WHO tobacco control treaty |
International Journa... |
2003 |
Gibbs T, Ross L |
Illicit drug use related attendances at accident and emergency service... |
Health Bull (Edinb) |
2003 |
Mlinar B, Corradetti R |
Endogenous 5-HT, released by MDMA through serotonin transporter- and s... |
Eur J Neurosci |
2003 |
Murray RA, Doering PL, Bo... |
Putting an Ecstasy test kit to the test: harm reduction or harm induct... |
Pharmacotherapy |
2003 |
Cameron D |
Much, much more important than that |
Addiction Reasearch ... |
2003 |
Tatarsky A |
Harm reduction psychotherapy: extending the reach of traditional subst... |
J Subst Abuse Treat |
2003 |
Hasler F , Grimberg U, Be... |
Acute psychological and physiological effects of psilocybin in healthy... |
Psychopharmacology |
2004 |
Macleod J, Oakes R, Copel... |
Psychological and social sequelae of cannabis and other illicit drug u... |
Lancet |
2004 |
Khorana N, Pullagurla MR,... |
Pharmacological and neurochemical evidence for antidepressant-likeeffe... |
Pharmacology, Bioche... |
2004 |
Schruers K, Griez E |
The effects of tianeptine or paroxetine on 35 CO2 provoked panic in pa... |
J Psychopharmacol |
2004 |
Gamma A, Jerome L, Liecht... |
Is ecstasy perceived to be safe? A critical survey |
Drug and Alcohol Dep... |
2005 |
Benveniste H, Fowler JS, ... |
Maternal and fetal 11C-cocaine uptake and kinetics measured in vivo by... |
J Nucl Med |
2005 |
Segura M, Farre M, Pichin... |
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetami... |
Clin Pharmacokinet |
2005 |
Donovan JL, DeVane CL, Ma... |
Modafinil influences the pharmacokinetics of intravenous cocaine in he... |
Clin Pharmacokinet |
2005 |
McCann UD, Szabo Z, Secki... |
Quantitative PET Studies of the Serotonin Transporter in MDMA Users an... |
Neuropsychopharmacol... |
2005 |
Gresch PJ, Smith RL, Barr... |
Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with ... |
Neuropsychopharmacol... |
2005 |
Schifano F, Deluca P, Ago... |
New trends in the cyber and street market of recreational drugs? The c... |
J Psychopharmacol |
2005 |
Schifano F, Deluca P, Ago... |
New trends in the cyber and street market of recreational drugs? The c... |
J Psychopharmacol |
2005 |
Biederman J, Swanson JM, ... |
Efficacy and safety of modafinil film-coated tablets in children and a... |
Pediatrics |
2005 |
Copeland J, Dillon P, Gas... |
Ecstasy and the concomitant use of pharmaceuticals |
Addict Behav |
2006 |
Nordt C, Stohler R |
Incidence of heroin use in Zurich, Switzerland: a treatment case regis... |
Lancet |
2006 |
Schifano F, Deluca P, Bal... |
Drugs on the web; the Psychonaut 2002 EU project |
Prog Neuropsychophar... |
2006 |
Sheridan J, Butler R, Wil... |
Legal piperazine-containing party pills--a new trend in substance misu... |
Drug Alcohol Rev |
2007 |
Allott K, Redman J |
Are there sex differences associated with the effects of ecstasy/3,4-m... |
Neurosci Biobehav Re... |
2007 |
Jager G, de Win MM, Verva... |
Incidental use of ecstasy: no evidence for harmful effects on cognitiv... |
Psychopharmacology (... |
2007 |
Vaglenova J, Pandiella N,... |
Aniracetam reversed learning and memory deficits following prenatal et... |
Neuropsychopharmacol... |
2008 |
Tupper KW |
Teaching teachers to just say know: Reflections on drug education |
Teaching and Techer ... |
2008 |
Tupper KW |
The globalization of ayahuasca: harm reduction or benefit maximization... |
Int J Drug Policy |
2008 |
Smith Z, Moore K, Measham... |
MDMA powder, pills and crystal: the persistence of ecstasy and the pov... |
Drugs and Alcohol To... |
2009 |
Bhide NS, Lipton JW, Cunn... |
Repeated exposure to MDMA provides neuroprotection against subsequent ... |
Brain Res |
2009 |
Lucas P |
Moral regulation and the presumption of guilt in Health Canada's medic... |
Int J Drug Policy |
2009 |
Karila L, Reynaud M |
GHB and synthetic cathinones: clinical effects and potential consequen... |
Drug Test Anal |
2010 |
Sumnall HR, Evans-Brown M... |
Social, policy, and public health perspectives on new psychoactive sub... |
Drug Test Anal |
2011 |
Van Hout MC, Bingham T |
'A Costly Turn On': Patterns of use and perceived consequences of meph... |
Int J Drug Policy |
2012 |
Winstock AR, Mitcheson L |
New recreational drugs and the primary care approach to patients who u... |
BMJ |
2012 |
Kayser B, Broers B |
The Olympics and harm reduction? |
Harm Reduct J |
2012 |
Absalom N, Eghorn LF, Vil... |
α4βδ GABAA receptors are high-affinity targets for ^... |
Proc Natl Acad Sci U... |
2012 |
Moore K, Dargan PI, Wood ... |
Do novel psychoactive substances displace established club drugs, supp... |
Eur Addict Res |
2013 |
Simojoki K, Alho H |
A Five-Year Follow-up of Buprenorphine Abuse Potential |
J Alcoholism Drug De... |
2013 |
Kerr T, Small W, Hyshka E... |
'It's more about the heroin': injection drug users' response to an ove... |
Addiction |
2013 |
Dietze P |
Commentary on Kerr et al(2013): advertising high-potency heroin |
Addiction |
2013 |
González D, Ventura M, Ca... |
Consumption of new psychoactive substances in a Spanish sample of rese... |
Hum Psychopharmacol |
2013 |
Soussan C, Kjellgren A |
Harm reduction and knowledge exchange-a qualitative analysis of drug-r... |
Harm Reduct J |
2014 |
Van Hout MC |
An Internet Study of User's Experiences of the Synthetic Cathinone 4-M... |
J Psychoactive Drugs |
2014 |
Van Hout MC |
Nod and wave: an Internet study of the codeine intoxication phenomenon |
Int J Drug Policy |
2015 |
Van Hout MC, Hearne E |
Word of mouse: indigenous harm reduction and online consumerism of the... |
J Psychoactive Drugs |
2015 |
Gonzalez D, Torrens M, Fa... |
Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions |
BioMed Research Inte... |
2015 |
D'Agnone O |
What have we learned and what can we do about NPS? |
Drugs and Alcohol To... |
2015 |
Davis CS, Green TC, Zalle... |
Addressing the overdose epidemic requires timely access to data to gui... |
Drug Alcohol Rev |
2015 |
Swogger MT, Hart E, Erowi... |
Experiences of Kratom Users: A Qualitative Analysis |
J Psychoactive Drugs |
2015 |
Palamar JJ, Su MK, Hoffma... |
Characteristics of novel psychoactive substance exposures reported to ... |
Am J Drug Alcohol Ab... |
2015 |
Racz J, Csak R, Toth KT, ... |
Veni, vidi, vici: The appearance and dominance of new psychoactive sub... |
Drug Alcohol Depend |
2016 |
Palamar JJ, Salomone A, V... |
Detection of bath salts and other novel psychoactive substances in hai... |
Drug Alcohol Depend |
2016 |
Brunt TM, Nagy C, Bücheli... |
Drug testing in Europe: monitoring results of the Trans European Drug ... |
Drug Test Anal |
2016 |
Marshall BD, Green TC, Ye... |
Harm reduction for young people who use prescription opioids extra-med... |
Int J Drug Policy |
2016 |
Csete J, Kamarulzaman A, ... |
Public health and international drug policy |
Lancet |
2016 |
Vidal Giné C, Fernández C... |
Patterns of use, harm reduction strategies, and their relation to risk... |
Am J Drug Alcohol Ab... |
2016 |